Company: GIFLF
Filing Date: 2025-02-26
Form Type: 6-K
Source: 0001104659-25-017501
Chunk: 9

Company: Grifols SA
Filing Date: 2025-02-26
Form: 6-K
Chunk 9
---
 markets Diagnostic - 2.0% Q4’24 +0.7 % 1 FY ’24 Introductory Remarks Business Performance Financials Final remarks Annex Opening Remarks Revenue Growth Accelerated in 2024, Reaching Record Levels

- 8 - Q4 2024 Results Biopharma IG Leads Biopharma's €6.1+ Bn Double - Digit Growth Portfolio Introductory Remarks Business Performance Financials Final remarks Annex • IVIG (+1 4 %) strong demand driven by the U.S. and international markets • SCIG (+56%) continued strong momentum led by the EU recent launches • Q4 Growth driven by strong demand for specialty proteins (e.g. Rabies) • Ongoing Improvement in Alpha - 1 momentum • Significant growth in other core markets in 2024 • Robust full year Albumin growth • Higher demand in China • Increased sales volumes from other core markets Q1’24 Q2’24 Q3’24 Q4’24 Strong growth driven by key proteins (Revenue growth at cc) Strong growth driven by key proteins (Revenue growth at cc) Biopharma Immunoglobulin Albumin Alpha - 1 and specialty proteins + 8.9% + 9.4% + 12.1% + 15.1% +12.5% +13.7% +16.6% +17.9% +7.1% +11.9% +11.7% +2.4% +4.4% - 4.1% +3,8% +16.5% +11.3% FY24 +15.3% FY24 +8.0% FY24 +4.9% FY24 Note: All figures are presented on a consolidated basis, and at constant currency (cc), excluding exchange rate fluctuations ove r the period.

- 9 - Q4 2024 Results Biopharma Leveraging Our Global Diversified Plasma Footprint for Reliable and Efficient Supply Introductory Remarks Business Performance Financials Final remarks Annex • Globally diverse plasma sources to increase plasma supply and support future growth • Successfully leveraged new technologies and process efficiencies • Reduced CPL through streamlined organization and efficient donor center operations • Optimized donor compensation while enhancing donor experience • Sustained manufacturing yield improvements Operational Efficiencies • Implemented in ~60% of US centers • Improve quality and satisfaction while optimizing donations • Increase plasma volume per donation • On track to fully improved nomogram US adoption Individualized Nomogram Rollover